10-Q: SS Innovations International Reports Q2 2026 Results, Net Loss Widens

SS Innovations International, Inc. reported increased revenues for the second quarter of 2026, but also a wider net loss driven by higher operating expenses, particularly in R&D and SG&A.

Summary

• SS Innovations International, Inc. (SSII) reported total revenues of $13.94 million for the three months ended June 30, 2026, an increase from $10.00 million in the same period of 2025.
• The company incurred a net loss of $2.66 million for Q2 2026, compared to a net loss of $0.26 million in Q2 2025.
• For the six months ended June 30, 2026, total revenues were $25.04 million, up from $15.12 million in the prior year period.
• The net loss for the six-month period widened to $6.24 million from $5.94 million in the comparable period of 2025.
• Operating expenses, including R&D and SG&A, saw significant increases in both the quarterly and year-to-date periods.
• The company disclosed substantial doubt about its ability to continue as a going concern, despite a recent private placement that generated $18.45 million in net proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, increased operating expenses, and the going concern disclosure, despite revenue growth.

Positives

• Total revenue increased by 39.4% to $13.94 million for the three months ended June 30, 2026, compared to $10.00 million for the same period in 2025.
• Total revenue increased by 65.6% to $25.04 million for the six months ended June 30, 2026, compared to $15.12 million for the same period in 2025.
• System sales revenue increased significantly, indicating growing adoption of the SSi Mantra surgical robotic system.
• The company successfully completed a private placement in March 2026, raising $18.45 million in net proceeds.
• Cash and cash equivalents increased to $13.65 million as of June 30, 2026, from $3.21 million as of December 31, 2025.

Negatives

• Net loss for the three months ended June 30, 2026, was $2.66 million, a substantial increase from $0.26 million in the prior year period.
• Net loss for the six months ended June 30, 2026, was $6.24 million, compared to $5.94 million in the prior year period.
• Research and development expenses increased significantly to $2.40 million for Q2 2026 from $0.50 million in Q2 2025.
• Selling, general, and administrative (SG&A) expenses increased to $4.45 million for Q2 2026 from $3.43 million in Q2 2025.
• Stock-based compensation expense increased to $5.32 million for the six months ended June 30, 2026, from $4.01 million in the prior year period.
• The company disclosed substantial doubt about its ability to continue as a going concern.
• The company's Indian operations generated higher taxable profits, leading to an increase in income tax expense.

Risks

• The company's existing cash resources and income from operations are not expected to provide sufficient funds to carry out operations and business development through the next twelve months.
• Management is making efforts to raise further funding, but there can be no assurance that the company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability.
• The company has a valuation allowance of $15.33 million against deferred tax assets in its U.S. operations due to a history of operating losses and limited visibility into future taxable income.
• The company is subject to ongoing legal proceedings related to transfer pricing adjustments, although management believes its position will be sustained.
• The company's ability to obtain regulatory approvals, such as U.S. FDA clearance and EU CE Mark certification, is critical for its expansion into regulated markets.

Future Outlook

The company expects to require substantial funds for scaling operations, capital expenditure for in-house machining and tooling capacity, and continued R&D in surgical robotics. Management plans to raise additional capital through further private or public offerings in the remainder of 2026. However, failure to secure funding could lead to limitations on expansion, R&D, and marketing activities. The company is also pursuing U.S. FDA and EU CE Mark approvals.

Management Comments

• The company's financial performance is largely driven by increasing awareness of the benefits of robotically assisted surgery, reduced learning curves for robotic surgeons and the affordability and accessibility of surgical robotic technology.
• Our manufacturing operations being based in India derive significant operating cost advantages in terms of availability of quality and cost-effective fabrication/3D printing solutions, electronic/electrical/mechanical components, outsourced services and skilled manpower.
• We expect to require substantial funds for scaling up our operations, incurring capital expenditure to have our own in-house machining and tooling capacity and to continue to finance our research and development work in the field of surgical robotics.
• If we are unable to do so and if we experience a shortfall in operating capital, we could be faced with having to limit our expansion plans, research and development efforts and marketing activities.

Industry Context

StockSavvy.ai notes that SS Innovations International is operating in the rapidly growing surgical robotics market, which is characterized by high R&D investment and a strong focus on regulatory approvals. The company's strategy to offer more affordable solutions, particularly leveraging cost advantages from its Indian manufacturing base, positions it to potentially capture market share in underserved regions. However, the significant increase in R&D expenses for regulatory activities highlights the challenges and costs associated with market entry in key regions like the US and EU.

Comparison to Industry Standards

• The company's revenue growth of 39.4% year-over-year for the quarter is strong, but the widening net loss indicates that achieving profitability remains a significant challenge, a common hurdle for early-stage medical device companies in the robotics sector.
• Increased R&D spending for regulatory approvals is standard in the medical device industry, but the scale of the increase ($1.9 million for the quarter) suggests a significant push towards market expansion, which requires substantial capital.
• The company's focus on affordability contrasts with some established players in the surgical robotics market who often command premium pricing. This strategy could be a differentiator if regulatory hurdles are cleared.
• The disclosure of substantial doubt about the going concern is a critical indicator. While common in early-stage companies, it highlights the need for successful capital raises and efficient operational management to meet industry standards for financial stability.

Management Changes

Legal Proceedings

• The company's Indian subsidiary received a draft assessment order related to proposed transfer pricing adjustment of $517,537 for the assessment year 2021-22. The adjustment was reduced to $501,243 after partial relief from the Dispute Resolution Panel. An appeal is pending before the Income Tax Appellate Tribunal (ITAT).

Related Party Transactions

• The company raised $28,000,000 in January 2025 via a 7% Convertible Promissory Note from an affiliate (Sushruta Private Limited).
• In February 2025, the company repaid $4,212,637 to Sushruta Pvt Ltd for promissory notes and interest.
• In February 2025, the company converted $22,000,000 in principal and accrued interest from convertible notes issued to Sushruta Pvt Ltd into 16,046,814 shares of common stock.
• In March 2025, the company converted $8,000,000 in principal and accrued interest from convertible notes issued to Sushruta Pvt Ltd into 5,811,554 shares of common stock.
• In March 2026, as part of a private placement, $2,000,000 was invested by Sushruta Private Limited for shares of common stock.
• In March 2026, as part of a private placement, $2,000,000 was invested by Dr. Frederic Moll for shares of common stock.
• In March 2026, as part of a private placement, $1,197,000 was invested by Tim Adams for shares of common stock.

Stakeholder Impact

• Shareholders: The widening net loss and going concern disclosure may negatively impact shareholder confidence and stock price. However, revenue growth and successful capital raises could be positive indicators for future value.
• Employees: Increased R&D and SG&A expenses may indicate continued investment in growth, potentially leading to future opportunities. Stock-based compensation expenses are significant.
• Creditors: The going concern disclosure raises concerns about the company's ability to meet its financial obligations, potentially impacting creditworthiness.
• Investors: The company's reliance on capital raises and the need for further funding highlight the risk associated with its growth strategy.

Next Steps

• Continue efforts to obtain U.S. FDA clearance and EU CE Mark certification.
• Scale up operations and incur capital expenditure for in-house machining and tooling capacity.
• Continue financing research and development work in surgical robotics.
• Seek additional capital through further private or public offerings.
• Expand presence in existing global markets and prepare for entry into the United States and European Union markets.

Key Dates

Recommendation

While revenue growth is positive, the widening net loss, increased operating expenses, and the explicit disclosure of substantial doubt about the company's ability to continue as a going concern present significant risks. The company's future performance is heavily dependent on successful capital raises and obtaining regulatory approvals. Investors should monitor these factors closely. A 'hold' recommendation reflects the balance between growth potential and significant financial and operational risks.

Keywords

surgical robotic system, SSi Mantra, medical device, revenue growth, net loss, operating expenses, R&D, FDA approval